Skip to main content

Fallon Marie E.'s Form 4 filing

Ginkgo Bioworks Holdings, Inc. (DNA) · filed Nov 7, 2022

Accession no.
0000899243-22-035327
Filed
Nov 7, 2022
Trade date
Nov 1-3, 2022
Filing delay
6 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $16.6K. It was filed 6 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Fallon Marie E.CIK 0001883686Officer (See remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 1, 2022Class A Common StockMOption exerciseAcquired+13,350–F1–140,884Direct
Nov 1, 2022Class A Common StockMOption exerciseAcquired+307–F2–141,191Direct
Nov 3, 2022Class A Common StockSSaleDisposed−6,279$2.65−$16,639.35134,912Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 1, 2022Class A Common StockMOption exerciseDisposed−13,350–F2–441,079Direct
Nov 1, 2022Class A Common StockMOption exerciseDisposed−307–F5–52,453Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 13,350 of the RSUs was satisfied on November 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.

Referenced by the price of 1 transaction in Table I.

F2

Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

F5

Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.

Referenced by the price of 1 transaction in Table II.

Remarks

Chief Accounting Officer

Read the full filing on SEC EDGAR (opens in a new tab)